Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the effect of low doses of pentavalent antimony
(meglumine antimoniate) to treat cutaneous leishmaniasis ulcers in patients older than 65
years. The hypothesis is that older patients may have a positive response with a lower dose
of pentavalent antimony, avoiding the frequent adverse events observed with the standard
dose. The design is that of an open uncontrolled trial enrolling 20 patients infected with
the parasite Leishmania braziliensis in an endemic area of the State of Bahia, Brazil. The
endpoint of cure or therapeutic failure will be evaluated at the third month of follow-up
after treatment to avoid the impact of spontaneous cure as a confounding factor.